TipRanks
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
Germany Market
VX1
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

23 Followers
See the Price Targets and Ratings of:

VX1 Analyst Ratings

Strong Buy
25Ratings
Strong Buy
21 Buy
3 Hold
1 Sell
Based on 25 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VX1 Stock 12 Month Forecast

Average Price Target

€505.77
▲(6.48% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €505.77 with a high forecast of €586.66 and a low forecast of €308.77. The average price target represents a 6.48% change from the last price of €475.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"307":"€307","377":"€377","447":"€447","517":"€517","587":"€587"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":586.66290025,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€586.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":505.76517400500006,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€505.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":308.7699475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€308.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[307,377,447,517,587],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,475,483.5894538653846,492.17890773076925,500.76836159615385,509.35781546153845,517.9472693269231,526.5367231923077,535.1261770576923,543.7156309230769,552.3050847884615,560.8945386538462,569.4839925192308,578.0734463846154,{"y":586.66290025,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,475,477.36655184653847,479.73310369307694,482.0996555396154,484.4662073861539,486.83275923269235,489.1993110792308,491.56586292576924,493.9324147723077,496.2989666188462,498.66551846538465,501.0320703119231,503.3986221584616,{"y":505.76517400500006,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,475,462.21307288461537,449.42614576923074,436.63921865384617,423.85229153846154,411.0653644230769,398.2784373076923,385.4915101923077,372.7045830769231,359.91765596153846,347.13072884615383,334.3438017307692,321.5568746153846,{"y":308.7699475,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":330.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":391.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":415,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":439.45,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":411.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€586.66Average Price Target€505.77Lowest Price Target€308.77
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:VX1
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
09/29/26
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Unicycive Therapeutics (UNCY)
UBS Analyst forecast on DE:VX1
Michael Yee
UBS
UBS
€516.09→€542.55
Buy
14.22%
Upside
Assigned
09/28/26
Vertex Pharmaceuticals price target raised to $615 from $585 at UBSVertex Pharmaceuticals price target raised to $615 from $585 at UBS
Bernstein Analyst forecast on DE:VX1
Jeffrey Walch
Bernstein
Bernstein
€536.38
Buy
12.92%
Upside
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Scholar Rock Holding (NASDAQ: SRRK) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Citi Analyst forecast on DE:VX1
Geoff Meacham
Citi
Citi
€516.09
Buy
8.65%
Upside
Reiterated
09/23/26
Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
BMO Capital Analyst forecast on DE:VX1
Evan Seigerman
BMO Capital
BMO Capital
€529.32
Buy
11.44%
Upside
Reiterated
09/23/26
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX)
Jefferies Analyst forecast on DE:VX1
Akash Tewari
Jefferies
Jefferies
€558.43→€564.61
Buy
18.86%
Upside
Reiterated
09/23/26
Jefferies Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on DE:VX1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€389.93
Hold
-17.91%
Downside
Reiterated
09/23/26
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity
Truist Financial Analyst forecast on DE:VX1
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/23/26
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (NASDAQ: EWTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN)
Scotiabank Analyst forecast on DE:VX1
Louise Chen
Scotiabank
Scotiabank
€492.27
Buy
3.64%
Upside
Reiterated
09/23/26
Scotiabank Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Barclays Analyst forecast on DE:VX1
Eliana Merle
Barclays
Barclays
€544.32
Buy
14.59%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), AnaptysBio (NASDAQ: ANAB) and Vertex Pharmaceuticals (NASDAQ: VRTX)
William Blair Analyst forecast on DE:VX1
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
H.C. Wainwright Analyst forecast on DE:VX1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€565.49
Buy
19.05%
Upside
Reiterated
09/22/26
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)
Morgan Stanley Analyst forecast on DE:VX1
Terence Flynn
Morgan Stanley
Morgan Stanley
€586.66
Buy
23.51%
Upside
Reiterated
09/22/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Celldex (NASDAQ: CLDX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Goldman Sachs Analyst forecast on DE:VX1
Salveen Richter
Goldman Sachs
Goldman Sachs
€576.08
Buy
21.28%
Upside
Reiterated
09/22/26
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
Stifel Nicolaus Analyst forecast on DE:VX1
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
―
Hold
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Roivant Sciences (NASDAQ: ROIV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:VX1
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
09/29/26
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Unicycive Therapeutics (UNCY)
UBS Analyst forecast on DE:VX1
Michael Yee
UBS
UBS
€516.09→€542.55
Buy
14.22%
Upside
Assigned
09/28/26
Vertex Pharmaceuticals price target raised to $615 from $585 at UBSVertex Pharmaceuticals price target raised to $615 from $585 at UBS
Bernstein Analyst forecast on DE:VX1
Jeffrey Walch
Bernstein
Bernstein
€536.38
Buy
12.92%
Upside
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Scholar Rock Holding (NASDAQ: SRRK) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Citi Analyst forecast on DE:VX1
Geoff Meacham
Citi
Citi
€516.09
Buy
8.65%
Upside
Reiterated
09/23/26
Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
BMO Capital Analyst forecast on DE:VX1
Evan Seigerman
BMO Capital
BMO Capital
€529.32
Buy
11.44%
Upside
Reiterated
09/23/26
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX)
Jefferies Analyst forecast on DE:VX1
Akash Tewari
Jefferies
Jefferies
€558.43→€564.61
Buy
18.86%
Upside
Reiterated
09/23/26
Jefferies Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on DE:VX1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€389.93
Hold
-17.91%
Downside
Reiterated
09/23/26
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity
Truist Financial Analyst forecast on DE:VX1
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/23/26
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (NASDAQ: EWTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN)
Scotiabank Analyst forecast on DE:VX1
Louise Chen
Scotiabank
Scotiabank
€492.27
Buy
3.64%
Upside
Reiterated
09/23/26
Scotiabank Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Barclays Analyst forecast on DE:VX1
Eliana Merle
Barclays
Barclays
€544.32
Buy
14.59%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), AnaptysBio (NASDAQ: ANAB) and Vertex Pharmaceuticals (NASDAQ: VRTX)
William Blair Analyst forecast on DE:VX1
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
H.C. Wainwright Analyst forecast on DE:VX1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€565.49
Buy
19.05%
Upside
Reiterated
09/22/26
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)
Morgan Stanley Analyst forecast on DE:VX1
Terence Flynn
Morgan Stanley
Morgan Stanley
€586.66
Buy
23.51%
Upside
Reiterated
09/22/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Celldex (NASDAQ: CLDX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Goldman Sachs Analyst forecast on DE:VX1
Salveen Richter
Goldman Sachs
Goldman Sachs
€576.08
Buy
21.28%
Upside
Reiterated
09/22/26
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
Stifel Nicolaus Analyst forecast on DE:VX1
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
―
Hold
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Roivant Sciences (NASDAQ: ROIV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OMCLOmnicell
KNSAKiniksa Pharmaceuticals
ACHVAchieve Life Sciences
AHCOAdaptHealth
ZVRAZevra Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Mohit BansalWells Fargo
Success Rate
25/34 ratings generated profit
74%
Average Return
+7.94%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 73.53% of your transactions generating a profit, with an average return of +7.94% per trade.
1 Year
Salveen RichterGoldman Sachs
Success Rate
19/24 ratings generated profit
79%
Average Return
+12.44%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 79.17% of your transactions generating a profit, with an average return of +12.44% per trade.
2 Years
Evan SeigermanBMO Capital
Success Rate
31/32 ratings generated profit
97%
Average Return
+22.81%
Copying Evan Seigerman's trades and holding each position for 2 Years would result in 96.88% of your transactions generating a profit, with an average return of +22.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VX1 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
42
33
50
59
70
Hold
11
9
9
9
9
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
53
42
60
69
80
In the current month, VX1 has received 70 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. VX1 average Analyst price target in the past 3 months is 505.77.
Each month's total comprises the sum of three months' worth of ratings.

VX1 Financial Forecast

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is €4.20 with a range of €3.25 to €4.57. The previous quarter’s EPS was €4.18. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for VX1 is €4.20 with a range of €3.25 to €4.57. The previous quarter’s EPS was €4.18. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is €3.01B with a range of €2.93B to €3.10B. The previous quarter’s sales results were €2.95B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.
Next quarter’s sales forecast for VX1 is €3.01B with a range of €2.93B to €3.10B. The previous quarter’s sales results were €2.95B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 505.77.
    What is DE:VX1’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals has 6.48% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vertex Pharmaceuticals a Buy, Sell or Hold?
          Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 21 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Vertex Pharmaceuticals’s share price target?
            The average share price target for Vertex Pharmaceuticals is 505.77. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €586.66 ,and the lowest forecast is €308.77. The average share price target represents 6.48% Increase from the current price of €475.
              What do analysts say about Vertex Pharmaceuticals?
              Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of Vertex Pharmaceuticals?
                To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.